Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 87
1991 214
1992 270
1993 224
1994 318
1995 248
1996 255
1997 303
1998 275
1999 409
2000 370
2001 380
2002 374
2003 349
2004 380
2005 534
2006 613
2007 609
2008 591
2009 668
2010 736
2011 740
2012 770
2013 647
2014 551
2015 551
2016 465
2017 567
2018 489
2019 379
2020 332
2021 296
2022 210
2023 184
2024 225
2025 279
2026 170
2027 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13,220 results

Results by year

Filters applied: . Clear all
Page 1
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.
Hortobagyi GN, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, Hee Park Y, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Martin M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Parnizari F, Zarate JP, Li Z, Waters S, Chakravartty A, Slamon D. Hortobagyi GN, et al. Ann Oncol. 2025 Feb;36(2):149-157. doi: 10.1016/j.annonc.2024.10.015. Epub 2024 Oct 21. Ann Oncol. 2025. PMID: 39442617 Free article. Clinical Trial.
Estrogens and breast cancer.
Kim J, Munster PN. Kim J, et al. Ann Oncol. 2025 Feb;36(2):134-148. doi: 10.1016/j.annonc.2024.10.824. Epub 2024 Nov 8. Ann Oncol. 2025. PMID: 39522613 Free PMC article. Review.
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC, Lorusso D, Moore RG, Freyer G, O'Cearbhaill RE, Heitz F, O'Malley DM, Redondo A, Shahin MS, Vulsteke C, Bradley WH, Haslund CA, Chase DM, Pisano C, Holman LL, Pérez MJR, DiSilvestro P, Gaba L, Herzog TJ, Bruchim I, Compton N, Shtessel L, Malinowska IA, González-Martín A. Monk BJ, et al. Ann Oncol. 2024 Nov;35(11):981-992. doi: 10.1016/j.annonc.2024.08.2241. Epub 2024 Sep 14. Ann Oncol. 2024. PMID: 39284381 Free PMC article. Clinical Trial.
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.
Powell MA, Bjørge L, Willmott L, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Gropp-Meier M, Stuckey A, Boere I, Gold MA, Segev Y, Gill SE, Gennigens C, Sebastianelli A, Shahin MS, Pothuri B, Monk BJ, Buscema J, Coleman RL, Slomovitz BM, Ring KL, Herzog TJ, Balas MM, Grimshaw M, Stevens S, Lai DW, McCourt C, Mirza MR. Powell MA, et al. Ann Oncol. 2024 Aug;35(8):728-738. doi: 10.1016/j.annonc.2024.05.546. Epub 2024 Jun 10. Ann Oncol. 2024. PMID: 38866180 Free article. Clinical Trial.
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial.
Conroy T, Castan F, Etienne PL, Rio E, Mesgouez-Nebout N, Evesque L, Vendrely V, Artignan X, Bouché O, Gargot D, Boige V, Bonichon-Lamichhane N, Louvet C, Morand C, de la Fouchardière C, Boilève A, Delaye M, Gourgou S, Pezzella V, Borg C. Conroy T, et al. Ann Oncol. 2024 Oct;35(10):873-881. doi: 10.1016/j.annonc.2024.06.019. Epub 2024 Jul 8. Ann Oncol. 2024. PMID: 38986769 Free article. Clinical Trial.
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial.
Harbeck N, Modi S, Pusztai L, Ohno S, Wu J, Kim SB, Yoshida A, Fabi A, Cao X, Joseph R, Li R, Żurawski B, Escrivá-de-Romaní S, Meneguetti R, Supavavej A, Chen SC, Liu Z, Kelly C, Curigliano G, Symmans WF, Gufran M, Ke J, Konpa A, Herbolsheimer P, Boileau JF; DESTINY-Breast11 Trial Investigators. Harbeck N, et al. Ann Oncol. 2026 Feb;37(2):166-179. doi: 10.1016/j.annonc.2025.10.019. Epub 2025 Oct 21. Ann Oncol. 2026. PMID: 41130363 Free article. Clinical Trial.
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.
Dent R, Shao Z, Schmid P, Cortes J, Cescon DW, Saji S, Jung KH, Bachelot T, Wang S, Ramírez EM, Basaran G, Stradella A, Mathiba R, Chen SC, Shen K, Wéber Á, Battelli N, Niikura N, Luo T, Chae YS, Fischbach N, Garbaos G, Patera A, Zhao K, Vuković P, Maxwell MJ, Traina T; TROPION-Breast02 investigators. Dent R, et al. Ann Oncol. 2026 Aug;37(8):1066-1080. doi: 10.1016/j.annonc.2026.03.008. Epub 2026 Apr 3. Ann Oncol. 2026. PMID: 41937088 Free article. Clinical Trial.
ctDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: results from the TOMBOLA trial.
Dyrskjøt L, Birkenkamp-Demtröder K, Nordentoft I, Strandgaard T, Lindskrog SV, Milling RV, Körner SK, Brandt SB, Knudsen M, Andreasen TG, Hansen CF, Lamy P, Lam G, Dohn LH, Fabrin K, Carus A, Petersen AC, Joensen UN, Pappot H, Holt PS, Jensen NV, Agerbæk M, Jensen JB. Dyrskjøt L, et al. Ann Oncol. 2026 May;37(5):712-724. doi: 10.1016/j.annonc.2025.12.018. Epub 2026 Jan 14. Ann Oncol. 2026. PMID: 41544704 Free article. Clinical Trial.
Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study.
André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, Alcaide-Garcia J, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Le DT, Yoshino T, Zuo Y, Fogelman D, Adelberg D, Diaz LA. André T, et al. Ann Oncol. 2025 Mar;36(3):277-284. doi: 10.1016/j.annonc.2024.11.012. Epub 2024 Dec 2. Ann Oncol. 2025. PMID: 39631622 Free article. Clinical Trial.
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial.
Tannir NM, Albigès L, McDermott DF, Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, Plimack ER, Porta C, George S, Donskov F, Atkins MB, Gurney H, Kollmannsberger CK, Grimm MO, Barrios C, Tomita Y, Castellano D, Grünwald V, Rini BI, Jiang R, Desilva H, Fedorov V, Lee CW, Motzer RJ. Tannir NM, et al. Ann Oncol. 2024 Nov;35(11):1026-1038. doi: 10.1016/j.annonc.2024.07.727. Epub 2024 Aug 2. Ann Oncol. 2024. PMID: 39098455 Free PMC article. Clinical Trial.
13,220 results
You have reached the last available page of results. Please see the User Guide for more information.